Comparison of prevalence and evolution of COVID-19 olfactory disorders in patients infected by D614 (wild) and B.1.1.7. Alpha variant: a brief report
Objectives To investigate the prevalence and the evolution of olfactory disorders (OD) related to coronavirus disease 2019 (COVID-19) in patients infected during the first and the second European waves. Methods From March 2020 to October 2020, COVID-19 patients with OD were recruited and followed ov...
Gespeichert in:
| Veröffentlicht in: | European archives of oto-rhino-laryngology 2023-07, Vol.280 (7), p.3461-3467 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3467 |
|---|---|
| container_issue | 7 |
| container_start_page | 3461 |
| container_title | European archives of oto-rhino-laryngology |
| container_volume | 280 |
| creator | Lechien, Jerome R. Wajsblat, Shannon Horoi, Mihaela Boscolo-Rizzo, Paolo Le Bon, Serge D. Vaira, Luigi A. Saussez, Sven |
| description | Objectives
To investigate the prevalence and the evolution of olfactory disorders (OD) related to coronavirus disease 2019 (COVID-19) in patients infected during the first and the second European waves.
Methods
From March 2020 to October 2020, COVID-19 patients with OD were recruited and followed over the 12-month post-infection. The following data were collected: demographic, treatments, vaccination status, and olfactory function. Olfaction was assessed with the Olfactory Disorder Questionnaire (ODQ), and threshold, discrimination, and identification (TDI) test. Outcomes were compared between patients of the first wave (group 1: wild/D614G virus) and the second wave (group 2: B.1.1.7. Alpha variant) at 1-, 3- and 12-month post-infection.
Results
Sixty patients completed the evaluations accounting for 33 and 27 patients in group 1 and 2, respectively. The 1-month TDI score (23.7 ± 5.3) was significantly lower in group 2 compared to group 1 (29.8 ± 8.7;
p =
0.017). Proportion of normosmic patients at 1-month post-infection was significantly higher in group 1 compared to group 2 (
p =
0.009). TDI scores only significantly increased from 1- to 3-month post-infection in anosmic and hyposmic patients. Focusing on There was a negative association between the 1-month ODQ and the 1-month TDI (
r
s
= − 0.493;
p =
0.012). ODQ was a significant predictor of TDI scores at 3- and 12-month post-infection. The 12-month prevalence of parosmia was 60.6% in group 1 and 42.4% in group 2, respectively. There was no significant influence of oral corticosteroid treatment, adherence to an olfactory training and vaccination status on the olfactory outcomes.
Conclusions
Patients of the second wave (Alpha B.1.1.7. variant) reported significant higher proportion of psychophysical test abnormalities at 1-month post-infection than patients infected during the first wave (D614G virus). |
| doi_str_mv | 10.1007/s00405-023-07923-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10029791</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2789236170</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-6b5f55f5dd966d956f3c1846e92ebac2aab11c5d1009cb9ab06403b29e97d67c3</originalsourceid><addsrcrecordid>eNp9UU1vFCEYJkZj1-of8GA4todZYWBg8WLWrdomm_SiXgkD73SnmYURZsZs_4f_V7ZTG_VgIEB4Pl54H4ReU7KkhMi3iRBOqoKUrCBS5fXuCVpQznjBZSmeogVRTBacS3mCXqR0SwipuGLP0QkTKtOYWqCfm7DvTWxT8Dg0uI8wmQ68BWy8wzCFbhzaGdtcf7u6KKjCoWuMHUI8YJd10UFMuPW4N0MLfjieG7ADOFwf8IWgHJ_9aDt3fu_4YUnzkEu87vqdwVMubfzwDhtcxxYaHKEPcXiJnjWmS_DqYT9FXz99_LK5LLbXn682621h-YoOhairpsrTOSWEU5VomKUrLkCVUBtbGlNTaiuXu6VsrUxNBCesLhUo6YS07BS9n337sd6Ds_n50XS6j-3exIMOptV_I77d6Zsw6exYKqlodjifHXb_6C7XW328I5wqKvhqOnLPHqrF8H2ENOh9myx0nfEQxqRLucopCipJppYz1caQUoTm0ZuSY3Gp5_B1Dl_fh6_vsujNn795lPxOOxPYTEgZ8jcQ9W0Yo88d_p_tL1yYuow</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2789236170</pqid></control><display><type>article</type><title>Comparison of prevalence and evolution of COVID-19 olfactory disorders in patients infected by D614 (wild) and B.1.1.7. Alpha variant: a brief report</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Lechien, Jerome R. ; Wajsblat, Shannon ; Horoi, Mihaela ; Boscolo-Rizzo, Paolo ; Le Bon, Serge D. ; Vaira, Luigi A. ; Saussez, Sven</creator><creatorcontrib>Lechien, Jerome R. ; Wajsblat, Shannon ; Horoi, Mihaela ; Boscolo-Rizzo, Paolo ; Le Bon, Serge D. ; Vaira, Luigi A. ; Saussez, Sven</creatorcontrib><description>Objectives
To investigate the prevalence and the evolution of olfactory disorders (OD) related to coronavirus disease 2019 (COVID-19) in patients infected during the first and the second European waves.
Methods
From March 2020 to October 2020, COVID-19 patients with OD were recruited and followed over the 12-month post-infection. The following data were collected: demographic, treatments, vaccination status, and olfactory function. Olfaction was assessed with the Olfactory Disorder Questionnaire (ODQ), and threshold, discrimination, and identification (TDI) test. Outcomes were compared between patients of the first wave (group 1: wild/D614G virus) and the second wave (group 2: B.1.1.7. Alpha variant) at 1-, 3- and 12-month post-infection.
Results
Sixty patients completed the evaluations accounting for 33 and 27 patients in group 1 and 2, respectively. The 1-month TDI score (23.7 ± 5.3) was significantly lower in group 2 compared to group 1 (29.8 ± 8.7;
p =
0.017). Proportion of normosmic patients at 1-month post-infection was significantly higher in group 1 compared to group 2 (
p =
0.009). TDI scores only significantly increased from 1- to 3-month post-infection in anosmic and hyposmic patients. Focusing on There was a negative association between the 1-month ODQ and the 1-month TDI (
r
s
= − 0.493;
p =
0.012). ODQ was a significant predictor of TDI scores at 3- and 12-month post-infection. The 12-month prevalence of parosmia was 60.6% in group 1 and 42.4% in group 2, respectively. There was no significant influence of oral corticosteroid treatment, adherence to an olfactory training and vaccination status on the olfactory outcomes.
Conclusions
Patients of the second wave (Alpha B.1.1.7. variant) reported significant higher proportion of psychophysical test abnormalities at 1-month post-infection than patients infected during the first wave (D614G virus).</description><identifier>ISSN: 0937-4477</identifier><identifier>EISSN: 1434-4726</identifier><identifier>DOI: 10.1007/s00405-023-07923-z</identifier><identifier>PMID: 36943439</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>COVID-19 - complications ; COVID-19 - epidemiology ; Head and Neck Surgery ; Humans ; Life Sciences ; Medicine ; Medicine & Public Health ; Neurosurgery ; Olfaction Disorders - complications ; Olfaction Disorders - etiology ; Otorhinolaryngology ; Prevalence ; SARS-CoV-2 ; Short Communication ; Smell</subject><ispartof>European archives of oto-rhino-laryngology, 2023-07, Vol.280 (7), p.3461-3467</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. corrected publication 2023</rights><rights>2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-6b5f55f5dd966d956f3c1846e92ebac2aab11c5d1009cb9ab06403b29e97d67c3</citedby><cites>FETCH-LOGICAL-c481t-6b5f55f5dd966d956f3c1846e92ebac2aab11c5d1009cb9ab06403b29e97d67c3</cites><orcidid>0000-0002-0845-0845 ; 0000-0002-4635-7959 ; 0000-0002-7789-145X ; 0000-0002-3655-1854</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00405-023-07923-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00405-023-07923-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36943439$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04191648$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Lechien, Jerome R.</creatorcontrib><creatorcontrib>Wajsblat, Shannon</creatorcontrib><creatorcontrib>Horoi, Mihaela</creatorcontrib><creatorcontrib>Boscolo-Rizzo, Paolo</creatorcontrib><creatorcontrib>Le Bon, Serge D.</creatorcontrib><creatorcontrib>Vaira, Luigi A.</creatorcontrib><creatorcontrib>Saussez, Sven</creatorcontrib><title>Comparison of prevalence and evolution of COVID-19 olfactory disorders in patients infected by D614 (wild) and B.1.1.7. Alpha variant: a brief report</title><title>European archives of oto-rhino-laryngology</title><addtitle>Eur Arch Otorhinolaryngol</addtitle><addtitle>Eur Arch Otorhinolaryngol</addtitle><description>Objectives
To investigate the prevalence and the evolution of olfactory disorders (OD) related to coronavirus disease 2019 (COVID-19) in patients infected during the first and the second European waves.
Methods
From March 2020 to October 2020, COVID-19 patients with OD were recruited and followed over the 12-month post-infection. The following data were collected: demographic, treatments, vaccination status, and olfactory function. Olfaction was assessed with the Olfactory Disorder Questionnaire (ODQ), and threshold, discrimination, and identification (TDI) test. Outcomes were compared between patients of the first wave (group 1: wild/D614G virus) and the second wave (group 2: B.1.1.7. Alpha variant) at 1-, 3- and 12-month post-infection.
Results
Sixty patients completed the evaluations accounting for 33 and 27 patients in group 1 and 2, respectively. The 1-month TDI score (23.7 ± 5.3) was significantly lower in group 2 compared to group 1 (29.8 ± 8.7;
p =
0.017). Proportion of normosmic patients at 1-month post-infection was significantly higher in group 1 compared to group 2 (
p =
0.009). TDI scores only significantly increased from 1- to 3-month post-infection in anosmic and hyposmic patients. Focusing on There was a negative association between the 1-month ODQ and the 1-month TDI (
r
s
= − 0.493;
p =
0.012). ODQ was a significant predictor of TDI scores at 3- and 12-month post-infection. The 12-month prevalence of parosmia was 60.6% in group 1 and 42.4% in group 2, respectively. There was no significant influence of oral corticosteroid treatment, adherence to an olfactory training and vaccination status on the olfactory outcomes.
Conclusions
Patients of the second wave (Alpha B.1.1.7. variant) reported significant higher proportion of psychophysical test abnormalities at 1-month post-infection than patients infected during the first wave (D614G virus).</description><subject>COVID-19 - complications</subject><subject>COVID-19 - epidemiology</subject><subject>Head and Neck Surgery</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurosurgery</subject><subject>Olfaction Disorders - complications</subject><subject>Olfaction Disorders - etiology</subject><subject>Otorhinolaryngology</subject><subject>Prevalence</subject><subject>SARS-CoV-2</subject><subject>Short Communication</subject><subject>Smell</subject><issn>0937-4477</issn><issn>1434-4726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UU1vFCEYJkZj1-of8GA4todZYWBg8WLWrdomm_SiXgkD73SnmYURZsZs_4f_V7ZTG_VgIEB4Pl54H4ReU7KkhMi3iRBOqoKUrCBS5fXuCVpQznjBZSmeogVRTBacS3mCXqR0SwipuGLP0QkTKtOYWqCfm7DvTWxT8Dg0uI8wmQ68BWy8wzCFbhzaGdtcf7u6KKjCoWuMHUI8YJd10UFMuPW4N0MLfjieG7ADOFwf8IWgHJ_9aDt3fu_4YUnzkEu87vqdwVMubfzwDhtcxxYaHKEPcXiJnjWmS_DqYT9FXz99_LK5LLbXn682621h-YoOhairpsrTOSWEU5VomKUrLkCVUBtbGlNTaiuXu6VsrUxNBCesLhUo6YS07BS9n337sd6Ds_n50XS6j-3exIMOptV_I77d6Zsw6exYKqlodjifHXb_6C7XW328I5wqKvhqOnLPHqrF8H2ENOh9myx0nfEQxqRLucopCipJppYz1caQUoTm0ZuSY3Gp5_B1Dl_fh6_vsujNn795lPxOOxPYTEgZ8jcQ9W0Yo88d_p_tL1yYuow</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>Lechien, Jerome R.</creator><creator>Wajsblat, Shannon</creator><creator>Horoi, Mihaela</creator><creator>Boscolo-Rizzo, Paolo</creator><creator>Le Bon, Serge D.</creator><creator>Vaira, Luigi A.</creator><creator>Saussez, Sven</creator><general>Springer Berlin Heidelberg</general><general>Springer Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0845-0845</orcidid><orcidid>https://orcid.org/0000-0002-4635-7959</orcidid><orcidid>https://orcid.org/0000-0002-7789-145X</orcidid><orcidid>https://orcid.org/0000-0002-3655-1854</orcidid></search><sort><creationdate>20230701</creationdate><title>Comparison of prevalence and evolution of COVID-19 olfactory disorders in patients infected by D614 (wild) and B.1.1.7. Alpha variant: a brief report</title><author>Lechien, Jerome R. ; Wajsblat, Shannon ; Horoi, Mihaela ; Boscolo-Rizzo, Paolo ; Le Bon, Serge D. ; Vaira, Luigi A. ; Saussez, Sven</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-6b5f55f5dd966d956f3c1846e92ebac2aab11c5d1009cb9ab06403b29e97d67c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>COVID-19 - complications</topic><topic>COVID-19 - epidemiology</topic><topic>Head and Neck Surgery</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurosurgery</topic><topic>Olfaction Disorders - complications</topic><topic>Olfaction Disorders - etiology</topic><topic>Otorhinolaryngology</topic><topic>Prevalence</topic><topic>SARS-CoV-2</topic><topic>Short Communication</topic><topic>Smell</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lechien, Jerome R.</creatorcontrib><creatorcontrib>Wajsblat, Shannon</creatorcontrib><creatorcontrib>Horoi, Mihaela</creatorcontrib><creatorcontrib>Boscolo-Rizzo, Paolo</creatorcontrib><creatorcontrib>Le Bon, Serge D.</creatorcontrib><creatorcontrib>Vaira, Luigi A.</creatorcontrib><creatorcontrib>Saussez, Sven</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European archives of oto-rhino-laryngology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lechien, Jerome R.</au><au>Wajsblat, Shannon</au><au>Horoi, Mihaela</au><au>Boscolo-Rizzo, Paolo</au><au>Le Bon, Serge D.</au><au>Vaira, Luigi A.</au><au>Saussez, Sven</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of prevalence and evolution of COVID-19 olfactory disorders in patients infected by D614 (wild) and B.1.1.7. Alpha variant: a brief report</atitle><jtitle>European archives of oto-rhino-laryngology</jtitle><stitle>Eur Arch Otorhinolaryngol</stitle><addtitle>Eur Arch Otorhinolaryngol</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>280</volume><issue>7</issue><spage>3461</spage><epage>3467</epage><pages>3461-3467</pages><issn>0937-4477</issn><eissn>1434-4726</eissn><abstract>Objectives
To investigate the prevalence and the evolution of olfactory disorders (OD) related to coronavirus disease 2019 (COVID-19) in patients infected during the first and the second European waves.
Methods
From March 2020 to October 2020, COVID-19 patients with OD were recruited and followed over the 12-month post-infection. The following data were collected: demographic, treatments, vaccination status, and olfactory function. Olfaction was assessed with the Olfactory Disorder Questionnaire (ODQ), and threshold, discrimination, and identification (TDI) test. Outcomes were compared between patients of the first wave (group 1: wild/D614G virus) and the second wave (group 2: B.1.1.7. Alpha variant) at 1-, 3- and 12-month post-infection.
Results
Sixty patients completed the evaluations accounting for 33 and 27 patients in group 1 and 2, respectively. The 1-month TDI score (23.7 ± 5.3) was significantly lower in group 2 compared to group 1 (29.8 ± 8.7;
p =
0.017). Proportion of normosmic patients at 1-month post-infection was significantly higher in group 1 compared to group 2 (
p =
0.009). TDI scores only significantly increased from 1- to 3-month post-infection in anosmic and hyposmic patients. Focusing on There was a negative association between the 1-month ODQ and the 1-month TDI (
r
s
= − 0.493;
p =
0.012). ODQ was a significant predictor of TDI scores at 3- and 12-month post-infection. The 12-month prevalence of parosmia was 60.6% in group 1 and 42.4% in group 2, respectively. There was no significant influence of oral corticosteroid treatment, adherence to an olfactory training and vaccination status on the olfactory outcomes.
Conclusions
Patients of the second wave (Alpha B.1.1.7. variant) reported significant higher proportion of psychophysical test abnormalities at 1-month post-infection than patients infected during the first wave (D614G virus).</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>36943439</pmid><doi>10.1007/s00405-023-07923-z</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0845-0845</orcidid><orcidid>https://orcid.org/0000-0002-4635-7959</orcidid><orcidid>https://orcid.org/0000-0002-7789-145X</orcidid><orcidid>https://orcid.org/0000-0002-3655-1854</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-4477 |
| ispartof | European archives of oto-rhino-laryngology, 2023-07, Vol.280 (7), p.3461-3467 |
| issn | 0937-4477 1434-4726 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10029791 |
| source | MEDLINE; SpringerLink Journals |
| subjects | COVID-19 - complications COVID-19 - epidemiology Head and Neck Surgery Humans Life Sciences Medicine Medicine & Public Health Neurosurgery Olfaction Disorders - complications Olfaction Disorders - etiology Otorhinolaryngology Prevalence SARS-CoV-2 Short Communication Smell |
| title | Comparison of prevalence and evolution of COVID-19 olfactory disorders in patients infected by D614 (wild) and B.1.1.7. Alpha variant: a brief report |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T05%3A11%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20prevalence%20and%20evolution%20of%20COVID-19%20olfactory%20disorders%20in%20patients%20infected%20by%20D614%20(wild)%20and%20B.1.1.7.%20Alpha%20variant:%20a%20brief%20report&rft.jtitle=European%20archives%20of%20oto-rhino-laryngology&rft.au=Lechien,%20Jerome%20R.&rft.date=2023-07-01&rft.volume=280&rft.issue=7&rft.spage=3461&rft.epage=3467&rft.pages=3461-3467&rft.issn=0937-4477&rft.eissn=1434-4726&rft_id=info:doi/10.1007/s00405-023-07923-z&rft_dat=%3Cproquest_pubme%3E2789236170%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2789236170&rft_id=info:pmid/36943439&rfr_iscdi=true |